Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2008 Apr;7(4):972-9. doi: 10.1158/1535-7163.MCT-07-2141. Epub 2008 Mar 28.

2.

Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.

Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ.

Carcinogenesis. 1998 Aug;19(8):1345-51.

PMID:
9744527
3.

Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96.

4.

Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.

Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ.

Carcinogenesis. 2005 Feb;26(2):441-8. Epub 2004 Dec 9.

PMID:
15591091
5.
6.

Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.

7.

Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.

Van Ginckel R, Janssens B, Callens M, Goeminne N, Wouters L, De Coster R.

Cancer Chemother Pharmacol. 1996;38(1):21-8.

PMID:
8603447
8.

Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD.

Carcinogenesis. 2006 Jun;27(6):1232-9. Epub 2005 Dec 12.

PMID:
16344269
9.

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.

Cancer Res. 1998 Feb 1;58(3):479-84.

10.

Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.

Rodríguez-Burford C, Lubet RA, Eto I, Juliana MM, Kelloff GJ, Grubbs CJ, Steele VE.

Carcinogenesis. 1999 Jan;20(1):71-6.

PMID:
9934852
11.
12.

Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.

Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC.

Anticancer Res. 1992 Jul-Aug;12(4):1147-53.

PMID:
1386970
13.

9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.

Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, Atigadda VR, Vines KK, Brouillette WJ, Muccio DD.

Cancer Lett. 2003 Nov 10;201(1):17-24.

PMID:
14580682
14.

Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.

Knott KK, McGinley JN, Lubet RA, Steele VE, Thompson HJ.

Breast Cancer Res Treat. 2001 Dec;70(3):171-83.

PMID:
11804181
15.

Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.

Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, Kelloff G, Lubet R.

Breast Cancer Res Treat. 2000 Mar;60(2):117-28.

PMID:
10845274
16.

Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.

Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, Ericson ME, Bode AM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1190-7. doi: 10.1158/1940-6207.CAPR-10-0330. Epub 2011 Jul 26.

17.

Sulfone metabolite of sulindac inhibits mammary carcinogenesis.

Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ.

Cancer Res. 1997 Jan 15;57(2):267-71.

18.

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2006 Apr;5(4):1073-8.

20.

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2018 Mar 14. doi: 10.3892/or.2018.6313. [Epub ahead of print]

PMID:
29565450

Supplemental Content

Support Center